Connect with us
img

Super News

Bristol-Myers releases mixed Opdivo lung cancer results

Bristol-Myers releases mixed Opdivo lung cancer results

BUSINESS NEWS

Bristol-Myers releases mixed Opdivo lung cancer results

[ad_1]

A researcher in a Bristol-Myers Squibb laboratory. The drugs — ipilimumab (brand name Yervoy) and nivolumab (Opdivo) — belong to a class called checkpoint inhibitors and are made by Bristol-Myers Squibb.

Emile Wamsteker | Bloomberg | Getty Images

Bristol-Myers released mixed results on Wednesday from trials testing the survival benefit of its immunotherapy Opdivo in combination with either chemotherapy or its other immuno-oncology drug, Yervoy, as an initial treatment for advanced lung cancer.

The U.S. drugmaker said that Opdivo combined with chemotherapy failed to extend overall survival more than chemotherapy alone in patients with advanced non-squamous non-small cell lung cancer (NSCLC).

The result sent Bristol-Myers shares 3% lower in extended trading, as it is likely to further solidify the domination of rival drug Keytruda from Merck as an initial treatment for advanced lung cancer, by far the most lucrative oncology market.

Both multibillion-dollar sellers are already approved for lung and several other types of cancer.

Opdivo did demonstrate an improvement in overall survival in combination with Yervoy in lung cancer patients whose tumors expressed at least 1% of the PD-L1 protein that the drug is designed to target. That accounts for about 70% of NSCLC patients, the company said.

Merck shares rose about 1% in after hours trading.

[ad_2]

Source link

Continue Reading
You may also like...

More in BUSINESS NEWS

To Top
error: Content is protected !!